<DOC>
	<DOCNO>NCT00509769</DOCNO>
	<brief_summary>This multi-institutional , open-label , single-arm , Phase II study trastuzumab emtansine ( T-DM1 ) administer intravenous ( IV ) infusion patient human epidermal growth factor receptor 2 ( HER2 ) -positive metastatic breast cancer ( MBC ) .</brief_summary>
	<brief_title>A Study Trastuzumab Emtansine ( Trastuzumab-MCC-DM1 ) Administered Intravenously Patients With Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Signed informed consent form . Human epidermal growth factor receptor 2 ( HER2 ) positive metastatic breast cancer ( MBC ) ; tissue ( slides block ) available HER2 confirmation . History progression HER2directed therapy treatment HER2positive breast cancer . At least 1 , 3 , chemotherapy regimen MBC . Granulocyte count ≥ 1500/μL , platelet count ≥ 100,000/μL , hemoglobin ≥ 9 g/dL . Serum bilirubin ≤ 1.5 mg/dL , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ≤ 2.5x upper limit normal ( ULN ) . Serum creatinine ≤ 1.5 mg/dL creatinine clearance ≥ 60 mL/min . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Any chemotherapy , hormonal therapy , radiotherapy , immunotherapy , biological therapy treatment breast cancer within 2 week first study treatment . Prior cumulative doxorubicin dose &gt; 360 mg/m^2 equivalent . History significant cardiac disease , unstable angina , congestive heart failure ( CHF ) , myocardial infarction , ventricular arrythmia require medication .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Trastuzumab emtansine</keyword>
	<keyword>MBC</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>HER2</keyword>
</DOC>